yet the ‘the Future of Coverage and
Payment for Personalised Medicine
’ article states that “from the public
and payer perspective, the marginal cost of the benchtop chemistry is
only a small part of the test’s value
to the health care system, which is
measured in years of life extended,
quality of life and the avoidance of
drugs that are not helpful”. It seems
that once the finalised scheme of
personalised medicine takes off, it
is only natural that the tax payer
will feel both strain and benefit over
the new system, as there is a belief
13
that this new scheme of having
medicine personalised will be overall cheaper than the previous ‘trial
and error’ tactics that costs money
for improper medicine usage.
Overall, there is no doubt that the
use of personalised medicine will
improve health and maintenance of
wellbeing due to the ease in identifying diseases at early stages using
genetic information already logged
for medical personnel. Although,
there are some issues surround-